Biomarkers and outcomes for pembrolizumab/axitinib for kidney cancer
In this phase 1b study, he researchers were looking for [...]
Ipilimumub plus nivolumab combination after prior treatment with immune checkpoint inhibitors
This retrospective study published in the Journal of Clinical Oncology [...]
Immune-related adverse events and clinical outcome in kidney cancer treated with nivolumab
In a paper published in Clinical Genitourinary Cancer the link [...]
ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer
Results from a phase II international trial led by researchers [...]
First-line immunotherapy combination treatments for metastatic kidney cancer
A meta-analysis of four major clinical trials of immunotherapy combinations [...]
Axitinib first-line treatment of papillary renal cell carcinoma
The majority of renal cell carcinomas (RCCs) are a subtype [...]
Novel HIF-2a inhibitor for patients with advanced kidney cancer
In this interview with Practice Update, Dr Eric Jonasch from [...]
ASCO GU 2020: Five-year survival data for metastatic kidney cancer patients treated with nivolumab
Five-year follow-up results from the phase 3 CheckMate-025 study, which [...]
Combination PD-1 and PD-L1 inhibitors for kidney cancer are no more beneficial than PD-1 inhibitor alone
A recent phase II clinical trial has shown that combined [...]
